Sanuwave Q2 2026 revenue tops revised guidance range

Sanuwave Health, Inc. (NASDAQ: SNWV) reported preliminary, unaudited second-quarter 2026 revenue of $9.6 million to $9.8 million, above the high end of its revised guidance range of $8.5 million to $9.5 million, according to a press release.

The preliminary figures represent a decrease of approximately 3% to 5% compared with revenue of $10.1 million in the second quarter of 2025.

CEO Morgan Frank attributed capital sales weakness to stress in the company's customer base and the presence of used Ultramist systems in the secondary market. "The business played out largely as we had forecast with capital sales facing headwinds from stress in our customer base and from the sale of used Ultramist systems in our market," Frank said.

Frank noted that the company has been working to qualify, train, and support users who acquire systems through the secondary market, and is offering trade-in terms allowing used units to be exchanged for certified pre-owned systems carrying a manufacturer's warranty.

Frank also said that sales of consumable applicators reached record levels during the quarter in both unit volume and revenue. "Sales of consumable applicators set all time records for both unit sales and revenues, both by significant margins," he said.

The Eden Prairie, Minn.-based company said the preliminary results are based on management's initial analysis and may be subject to adjustment pending completion of quarter-end financial close and review procedures. Sanuwave said it expects to report full second-quarter earnings in August.

You May Also Be Interested In

• Trump: nominate Heidi Overton, MD, PhD, as our next FDA commissioner
• Cosmos Health posts 29% revenue gain in Q2 but widens net loss
• TJX stock drops as profit outlook falls short of analyst estimates